U.S. Federal Trade Commission

Emtricitabine ( FTC ), with trade name Emtriva (formerly Coviracil ), is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults and children. A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb ...

The FTC (Federal Trade Commission), in a recent report, proposed that the 12-14 years that are currently being allotted as a period exclusively for the innovation of products in biotech companies is much longer than required for the purpose. The report also ...

As the dust settles on the White House announcement yesterday of its health-care overhaul, here are some further details worthy of note in the proposal: The Federal Trade Commission would get power to block deals where a generic maker delays bringing a ...

Patent deals between generic and branded drug makers have been getting lot of attention lately on both sides of the Atlantic. Today, Pfizer took a turn in the spotlight.. Pfizer said that its record is clean and that it's cooperating with European ...

FTC and lawmakers say certain drug patent settlements cost consumers billions each yearThe Federal Trade Commission says patent settlements between drugmakers that cost U.S. consumers billions each year are on the rise.The agency reported Wednesday that the number of lucrative settlements between ...

Regulators don't seem to like it much when big drug companies pay generics shops in deals that determine when branded drugs will face generic competition. Today, for example, the head of the FTC and a few lawmakers will call on Congress to ...

In a recently published report, the Federal Trade Commission suggested that the current allotment of a 12- to 14-year regulatory exclusivity period for product innovation to develop products at biotech companies is?too long to promote innovation.? The same report, published June 4, ...

WASHINGTON (Reuters) - U.S. lawmakers tussled on Thursday over how long makers of biotechnology drugs should have an exclusive license for the expensive medicines in a hearing called to discuss a Federal Trade Commission report on the issue.The FTC, which specializes in ...

FTC pans biotech demands on generic competition, says would discourage development of new medsThe biotechnology industry's demand for up to 14 years of competition-free marketing before cheaper copies of their drugs can be launched is unnecessary and would discourage development of new ...

Topic: U.S. Federal Trade Commission

Emtricitabine

What Mouli Cohen has to say about biotech drugs and innovation

The Obama Plan, Day 2: Pay for Delay, Biologics, CBO Score

Turns Out, Pfizer Was Also Questioned in EU On Generic Deals

FTC wants ban on drug settlements in health bill

Big Pharma, Generic Competition and Cash

On the Brink of Generic Biotech Drugs, What's the Cost to Innovation?

U.S. lawmakers tussle over generic biologic drugs

FTC pans biotech demands for generic competition

Photo Gallery

From Around the Web

Video Gallery

Follow this Topic with...